Orismilast

DB19042InvestigationalSmall molecule

Orismilast is under investigation in clinical trial NCT05190419 (Study to Assess the Efficacy and Safety of Orismilast in Psoriasis).

Mechanism: Pharmacologically active on 3',5'-cyclic-AMP phosphodiesterase 4B, 3',5'-cyclic-AMP phosphodiesterase 4D, and cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4)
Curator reviewed
Formula / weight: C₁₉H₁₅Cl₂F₂NO₇S · 510.29 g/mol (avg)
Also known as: 2-(3,5-dichloro-1-oxido-4-pyridinyl)-1-(7-(difluoromethoxy)-2',3',5',6'-tetrahydro-1',1'-dioxidospiro(1,3-benzodioxole-2,4'-(4h)thiopyran)-4-yl)ethanone
Code names: LEO-32731

Resolves to

Compound

Structure

InChIKeyZININGNRPUGNSL-UHFFFAOYSA-NSMILES[O-][N+]1=CC(Cl)=C(CC(=O)C2=CC=C(OC(F)F)C3=C2OC2(CCS(=O)(=O)CC2)O3)C(Cl)=C1

Targets

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Orismilast, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.